Skip to content
OpenCapital
Get started

Aquestive Therapeutics, Inc. AQST Q2 2025 earnings

Reported August 11, 2025 · After market close

Revenue$10.0MMiss by $2.2MDiluted EPS-$0.14Beat by $0.04
Revenue estimate$12.2M
EPS estimate-$0.18

Next report

Aug 10, 2026 (In 4 weeks)
Revenue estimate$11.4M
EPS estimate-$0.10

Financials

Q2 2025

Income statement

See full
Revenue$10.0M-50.2%
Gross profit$5.4M-65.1%
Operating income-$11.4M-20,769%
Net income-$13.5M-394%
EPS (diluted)-$0.14-367%

Balance sheet

See full
Cash & equivalents$60.5M-32.6%
Total debt$59.8M+17.9%
Total equity-$72.6M-105%
Total assets$93.7M-20.3%

Cash flow

See full
Operating cash flow-$7.9M-13.0%
CapEx$107.0K+206%
Free cash flow-$8.0M-13.9%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$318.84M+34.7%
Enterprise value$318.08M+61.0%
P/S7.2×+3.2×

Profitability

See full
Gross margin61.1%-7.4pp
Operating margin-119.2%-165pp
Net margin-147.4%-257pp
FCF margin-113.3%-286pp

Returns & leverage

See full
Current ratio3.5×-4.0×

Segments

By product

See full
Manufacture and supply revenue$9.6M+18.0%
License and royalty revenue a$839.0K-92.5%
Co-development and research fees$378.0K-50.0%

By segment

See full
Reportable Segment$10.0M-50.2%

Versus estimates

Revenue

Q1 2026$14.4MBeat by $3.6MQ4 2025$13.0MMiss by $271.4KQ3 2025$12.8MMiss by $136.5K
Q2 2025$10.0MMiss by $2.2M
Q1 2025$8.7MMiss by $3.5MQ4 2024$11.9MMiss by $1.2M

Diluted EPS

Q1 2026-$0.07Beat by $0.07Q4 2025-$0.26Miss by $0.13Q3 2025-$0.14Miss by $0.03
Q2 2025-$0.14Beat by $0.04
Q1 2025-$0.24Miss by $0.07Q4 2024-$0.19Miss by $0.05

Ask the moment Aquestive Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Aquestive Therapeutics, Inc. report Q2 2025 earnings?
Aquestive Therapeutics, Inc. (AQST) reported Q2 2025 earnings on August 11, 2025 after market close.
What were Aquestive Therapeutics, Inc.'s Q2 2025 revenue and EPS?
Aquestive Therapeutics, Inc. reported revenue of $10.0M and diluted EPS of $-0.14 for Q2 2025.
Did Aquestive Therapeutics, Inc. beat estimates in Q2 2025?
Revenue missed the consensus estimate of $12.2M by $2.2M. EPS beat the consensus estimate of $-0.18 by $0.04.
How did Aquestive Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 50.2% from $20.1M a year earlier and diluted EPS declined 366.7% from $-0.03.
Where can I find Aquestive Therapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001398733-25-000013) directly on SEC EDGAR. The filing index links above go to sec.gov.